A (127) | B (8) | C (26) | D (12) | E (21) | F (6) | G (1) | H (10) | I (19) | L (8) | M (7) | N (3) | O (8) | P (15) | R (29) | S (35) | T (1) | U (5) | V (14)
Title Author Last update
Depemokimab as an Extended treatmeNt Duration Biologic in Adults with Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) roman
Depemokimab as an Extended treatmeNt Duration Biologic in Adults with Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) roman
Depemokimab as an Extended treatmeNt Duration biologic in Adults with Chronic Obstructive Pulmonary Disease (COPD) and Type 2 inflammation (ENDURA-2) roman
Depemokimab as an Extended treatmeNt Duration biologic in Adults with Chronic Obstructive Pulmonary Disease (COPD) and Type 2 inflammation (ENDURA-2) roman
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study (IMAGINE) ben
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial (DESTINY) admin
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial (DESTINY) admin
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial (DESTINY) roman
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial (DESTINY) roman
DESTINY: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial roman
Dose Exploration Study of GSK4532990 in Participants With NASH or Suspected NASH (SKYLINE) ben
Dose Exploration Study of GSK4532990 in Participants With Nonalcoholic Steatohepatitis (NASH) or Suspected NASH (SKYLINE) admin